SEC Form 4 · accession 0001193125-26-359349

PROKIDNEY CORP. · PROK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 18, 2026

Accepted (ET)

Aug 20, 2026 · 5:00 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001850270

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Class A Common Stock^F1	Aug 18, 2026	S	229,338	$1.3712	D	445,897	I	By Brian J. G. Pereira 2012 Irrevocable Trust
Class A Common Stock^F1	Aug 18, 2026	S	27,826	$1.3712	D	54,103	D
Class A Common Stock^F2	Aug 19, 2026	S	222,949	$1.4407	D	222,948	I	By Brian J. G. Pereira 2012 Irrevocable Trust
Class A Common Stock^F2	Aug 19, 2026	S	27,051	$1.4407	D	27,052	D
Class A Common Stock^F3	Aug 20, 2026	S	222,948	$1.4199	D	0	I	By Brian J. G. Pereira 2012 Irrevocable Trust
Class A Common Stock^F3	Aug 20, 2026	S	27,052	$1.4199	D	0	D

No Table II lines on this filing.

F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.345 to $1.40, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.50, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.38 to $1.47, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.